摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4-dihydro-2-dodecyl-6-methoxy-2,7,8-trimethyl-2H-benzopyran-5-carboxaldehyde | 389634-00-8

中文名称
——
中文别名
——
英文名称
3,4-dihydro-2-dodecyl-6-methoxy-2,7,8-trimethyl-2H-benzopyran-5-carboxaldehyde
英文别名
3,4-dihydro-2-dodecyl-6-methoxy-2,7,8-trimethyl-2H-1-benzopyran-5-carboxaldehyde;2-Dodecyl-6-methoxy-2,7,8-trimethyl-3,4-dihydrochromene-5-carbaldehyde
3,4-dihydro-2-dodecyl-6-methoxy-2,7,8-trimethyl-2H-benzopyran-5-carboxaldehyde化学式
CAS
389634-00-8
化学式
C26H42O3
mdl
——
分子量
402.618
InChiKey
GRXMVVDJTBLFTA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    8.8
  • 重原子数:
    29
  • 可旋转键数:
    13
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    35.5
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3,4-dihydro-2-dodecyl-6-methoxy-2,7,8-trimethyl-2H-benzopyran-5-carboxaldehydesodium chloritesodium dihydrogenphosphate氯化亚砜双氧水 、 sodium hydride 、 乙硫醇 作用下, 以 四氢呋喃N,N-二甲基甲酰胺乙腈 为溶剂, 反应 2.0h, 生成 N-(3,4-dihydro-2-dodecyl-6-hydroxy-2,7,8-trimethyl-2H-1-benzopyran-5-carbonyl)-N',N'-diethyl ethylenediamine
    参考文献:
    名称:
    Bifunctional agents for reperfusion arrhythmias: Novel hybrid vitamin E/Class I antiarrhythmics
    摘要:
    We have synthesized a series of hybrid compounds combining the pharmacophoric redox moieties of vitamin E and key features responsible for the antiarrhythmic properties of the class I antiarrhythmics procainamide and lidocaine. Procainamide analogue (2a) and lidocaine analogues (14a) and (14b) are very strong inhibitors of lipid peroxidation. All analogues tested at 100 or 30 muM enhanced the post ischemic recovery without inducing ventricular fibrillations while there was no evidence in our experiments for drug-induced pro-arrhythmia. In addition, they induced a widening of the QRS intervals. Our data suggest that the efficacy of the new compounds in preventing reperfusion arrhythmias could be attributed to their combined effects involving inhibition of free radical mediated damage coupled with antiarrhythmic properties. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2003.08.010
  • 作为产物:
    参考文献:
    名称:
    Bifunctional agents for reperfusion arrhythmias: Novel hybrid vitamin E/Class I antiarrhythmics
    摘要:
    We have synthesized a series of hybrid compounds combining the pharmacophoric redox moieties of vitamin E and key features responsible for the antiarrhythmic properties of the class I antiarrhythmics procainamide and lidocaine. Procainamide analogue (2a) and lidocaine analogues (14a) and (14b) are very strong inhibitors of lipid peroxidation. All analogues tested at 100 or 30 muM enhanced the post ischemic recovery without inducing ventricular fibrillations while there was no evidence in our experiments for drug-induced pro-arrhythmia. In addition, they induced a widening of the QRS intervals. Our data suggest that the efficacy of the new compounds in preventing reperfusion arrhythmias could be attributed to their combined effects involving inhibition of free radical mediated damage coupled with antiarrhythmic properties. (C) 2003 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2003.08.010
点击查看最新优质反应信息

文献信息

  • BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY
    申请人:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
    公开号:EP1301504B1
    公开(公告)日:2004-11-03
  • Bifunctional agents possessing antioxidant and antiarrhythmic activity
    申请人:——
    公开号:US20040259763A1
    公开(公告)日:2004-12-23
    The present invention relates to novel bifunctional agents possessing antioxidant and antiarrhytmic activity, methods for the synthesis of the same and their applications in treating ischemia-reperfusion injury, as well as a variety of disorders related to free radicals and/or arrhythmias. These bifunctional drugs should prefrentially segregate in the membrane and produce their antiarrhytmic effects while, at the same time, help in protecting the membrane lipids by scavenging free radicals. The present invention comprises compounds represented by Formula (I), wherein R 1 , R 2 , R 3 , R 4 , R 5 are further defined. 1
  • US7115657B2
    申请人:——
    公开号:US7115657B2
    公开(公告)日:2006-10-03
  • [EN] BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY<br/>[FR] AGENTS BIFONCTIONNELS A ACTIVITE ANTIOXYDANTE ET ANTIARYTHMIQUE
    申请人:UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA
    公开号:WO2002004438A1
    公开(公告)日:2002-01-17
    The present invention relates to novel bifunctional agents possessing antioxidant and antiarrhytmic activity, methods for the synthesis of the same and their applications in treating ischemia-reperfusion injury, as well as a variety of disorders related to free radicals and/or arrhythmias. These bifunctional drugs should preferentially segregate in the membrane and produce their antiarrhytmic effects while, at the same time, help in protecting the membrane lipids by scavenging free radicals. The present invention comprises compounds represented by Formula (I), wherein R1, R2, R3, R4, R5 are further defined.
  • Bifunctional agents for reperfusion arrhythmias: Novel hybrid vitamin E/Class I antiarrhythmics
    作者:Maria Koufaki、Theodora Calogeropoulou、Eleni Rekka、Michael Chryselis、Panagiota Papazafiri、Catherine Gaitanaki、Alexandros Makriyannis
    DOI:10.1016/j.bmc.2003.08.010
    日期:2003.11
    We have synthesized a series of hybrid compounds combining the pharmacophoric redox moieties of vitamin E and key features responsible for the antiarrhythmic properties of the class I antiarrhythmics procainamide and lidocaine. Procainamide analogue (2a) and lidocaine analogues (14a) and (14b) are very strong inhibitors of lipid peroxidation. All analogues tested at 100 or 30 muM enhanced the post ischemic recovery without inducing ventricular fibrillations while there was no evidence in our experiments for drug-induced pro-arrhythmia. In addition, they induced a widening of the QRS intervals. Our data suggest that the efficacy of the new compounds in preventing reperfusion arrhythmias could be attributed to their combined effects involving inhibition of free radical mediated damage coupled with antiarrhythmic properties. (C) 2003 Elsevier Ltd. All rights reserved.
查看更多